Science Corporation Successfully Implants First Vision-Restoring Chip in Stargardt Disease Patient
Science Corporation just made history. The company, led by former Neuralink president Max Hodak, has implanted its PRIMA vision-restoring microchip into its very first Stargardt disease patient. The milestone was announced live at TechCrunch Disrupt 2026 in San Francisco, where Hodak took the stage to walk through the details. It’s a big moment for the biotech space, man. What makes this especially interesting is how it ties into the growing conversation around What is AI and its role in advancing medical devices — honestly, the line between AI and biotech keeps blurring, and this implant proves it.
Stargardt disease is an inherited form of macular degeneration that robs patients of central vision over time. Think of it as the retinal cells slowly giving up the ghost. The PRIMA chip works by converting light into electrical signals that bypass damaged photoreceptors and stimulate the remaining healthy cells. It’s essentially a retinal prosthetic that feeds visual information straight to the brain. You know how people talk about neural interfaces being the future? Well, this is one step closer to that reality — seriously, it’s wild to see a device like this move from lab to human implantation this quickly.
The first-in-human surgery marks the beginning of a clinical trial phase that could pave the way for regulatory approval down the line. Science Corporation is already positioning PRIMA as part of a broader vision restoration platform, with plans to expand to additional patients. This isn’t just about restoring sight — it’s about proving that the kind of high-bandwidth neural interface work pioneered at companies like Neuralink can translate into real medical breakthroughs. The intersection of AI and AI Models in healthcare is something nobody’s ignoring anymore, and devices like PRIMA are bringing that closer to everyday reality. And if you’re curious about how these systems actually process and transmit data under the hood, understanding AI Tokens gives you a pretty solid foundation for grasping the computational side of it all.
- First-in-human success: Science Corporation’s PRIMA chip has been implanted in its inaugural Stargardt disease patient, opening the door for a broader clinical trial and potential FDA pathway.
- Neuralink DNA meets retina: Max Hodak’s background at Neuralink brings high-stakes BCI expertise to a completely different organ system — proof that the company’s tech transfer strategy is already bearing fruit.
- AI-biotech convergence is real: With AI-driven modeling and signal processing now embedded in implantable medical devices, the boundary between computer science and medicine is dissolving faster than most people realize.